Quick Search

 

 


 

 

Home > Result Summaries: Compounds > fosamprenavir > Result Summary for APV10025

Result Summary for APV10025

Result Summary
Protocol ID: APV10025
Clinical Study ID: APV10025
Official Title: A Phase I, Randomized, Open Label, Two Period, Two Sequence, Drug-Drug Interaction Study Comparing Steady-State Plasma Rifabutin Pharmacokinetics following Coadministration of Fosamprenavir 700mg + Ritonavir 100mg Twice Daily (BID) and Rifabutin 150mg Every Other Day (QOD) and following Administ ...
Phase: Phase 1
Study Indications or Diseases:
  • Infection, Human Immunodeficiency Virus
Generic Name: fosamprenavir
Trade/Product Name: Telzer,Telzir,Lexiva
Approved Drug Label: http://www.gsk.com/products.html
Results Summary: Click here to download result summary. Click here to download result summary.
Citations:
  • Chen Y, Ford SL, Shelton MJ, Lou Y, Borland J, Min SS, Yuen GJ. Pharmacokinetic Interaction Between Rifabutin (RFB) and Fosamprenavir (FPV)/ Ritonavir (RTV) in Healthy Subjects. The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Poster Number A-1199.

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.